US · HBIO
Harvard Bioscience, Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Holliston, MA 01746
- Website
- harvardbioscience.com
Price · as of 2024-12-31
$6.36
Market cap 27.44M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $35.84 | +463.52% |
| Intrinsic Value(DCF) | $0.33 | -94.81% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $2.10 | -67% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $3.24 | $34.93 | $11.43 | $5.24 | $21.79 |
| 2011 | $3.00 | $44.82 | $0.56 | $2.82 | $1.17 |
| 2012 | $4.32 | $33.24 | $0.00 | $2.77 | $0.84 |
| 2013 | $4.58 | $47.40 | $0.00 | $1.60 | $0.00 |
| 2014 | $5.22 | $37.09 | $0.00 | $2.10 | $0.83 |
| 2015 | $2.87 | $83.58 | $0.00 | $0.00 | $0.00 |
| 2016 | $2.65 | $54.64 | $0.00 | $0.37 | $0.00 |
| 2017 | $4.60 | $47.11 | $0.00 | $1.09 | $0.00 |
| 2018 | $3.72 | $25.31 | $0.00 | $0.21 | $0.00 |
| 2019 | $2.77 | $25.30 | $0.00 | $0.02 | $0.00 |
| 2020 | $6.42 | $27.09 | $0.00 | $0.00 | $0.71 |
| 2021 | $6.21 | $42.46 | $0.00 | $0.60 | $0.00 |
| 2022 | $2.67 | $68.76 | $0.00 | $0.00 | $0.00 |
| 2023 | $4.42 | $63.55 | $0.00 | $0.00 | $0.00 |
| 2024 | $0.82 | $35.84 | $0.00 | $0.00 | $2.10 |
AI valuation
Our deep-learning model estimates Harvard Bioscience, Inc.'s (HBIO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $35.84
- Current price
- $6.36
- AI upside
- +463.52%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.33
-94.81% upside
Graham-Dodd
—
— upside
Graham Formula
$2.10
-67% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| HBIO | Harvard Bioscience, Inc. | $6.36 | 27.44M | +464% | -95% | — | -67% | -2.88 | 0.56 | 0.38 | -51.62 | -1.16 | -8.67 | 58.18% | -6.60% | -13.18% | -18.19% | -5.77% | -9.40% | 0.70 | -1.94 | 0.82 | 0.35 | -27.40 | 24783.00% | -1614.00% | -11556.00% | -5.11% | 0.03 | -1.69% | 0.00% | 0.00% | 0.00% | -12.25 | -41.74 | 0.81 | -0.92 |
| CLGN | CollPlant Biotechnologies… | $0.57 | 7.18M | +8,539% | +137% | — | +21,233% | -2.30 | 2.84 | 74.26 | -1.89 | -1.72 | 2.87 | -417.09% | -3349.71% | -3225.05% | -79.46% | -364.64% | -62.87% | 0.23 | -1014.76 | 4.44 | 4.21 | 0.57 | 13387.00% | -9530.00% | 29214.00% | -38.11% | -4.75 | -308.10% | 0.00% | 0.00% | 0.00% | -1.71 | -2.02 | 57.12 | -6.47 |
| COSM | Cosmos Health Inc. | $0.39 | 10.71M | +8,441% | +650% | — | — | -0.61 | 0.40 | 0.18 | -1.53 | — | 0.59 | 7.92% | -28.56% | -29.73% | -53.43% | -38.56% | -26.90% | 0.48 | -15.36 | 0.99 | 0.63 | -0.83 | -4558.00% | 197.00% | -6720.00% | -82.82% | -0.30 | -20.18% | 63.07% | -38.30% | 63.07% | -1.37 | -2.62 | 0.39 | -2.69 |
| FEMY | Femasys Inc. | $0.57 | 16.78M | +4,489% | +5% | — | — | -1.78 | 14.49 | 20.50 | -2.29 | — | 14.92 | 66.55% | -1091.75% | -1155.03% | -182.18% | -369.29% | -93.61% | 3.23 | -11.09 | 0.93 | 0.46 | -0.24 | -968.00% | 5197.00% | 7686.00% | -60.49% | -2.27 | -419.54% | 0.00% | 0.00% | 0.00% | -2.10 | -1.85 | 22.95 | -16.97 |
| NCNA | NuCana plc | $2.16 | 13.12M | — | — | — | — | -41.51 | 132.44 | — | -34.78 | — | 210.00 | 0.00% | — | — | -182.30% | 1515.50% | -89.22% | 0.03 | — | 1.42 | 1.31 | 0.29 | -3771.00% | — | -2789.00% | -2.46% | -2.21 | 1524.22% | 0.00% | 0.00% | 0.00% | -34.28 | -40.29 | — | 27.59 |
| NXGL | NEXGEL, Inc. | $1.15 | 12.25M | +3,170% | +17,257% | — | — | -5.85 | 3.34 | 2.21 | -6.97 | — | 5.03 | 31.63% | -40.91% | -37.76% | -62.78% | -61.44% | -31.34% | 0.49 | -43.88 | 2.07 | 1.11 | -0.35 | -1071.00% | 11247.00% | 961.00% | -22.44% | -1.57 | -74.51% | 0.00% | 0.00% | 0.00% | -5.69 | -4.69 | 2.33 | 0.07 |
| NXL | Nexalin Technology, Inc. | $0.47 | 8.77M | +5,717% | +102% | — | — | -2.88 | 5.97 | 130.00 | -2.38 | -9.08 | 6.42 | 78.31% | -4596.14% | -4508.73% | -221.05% | -3380.55% | -193.70% | 0.00 | — | 7.25 | 6.39 | 0.07 | 3175.00% | 5235.00% | -1.00% | -17.98% | -7.21 | -1719.51% | 0.00% | 0.00% | 0.00% | -2.38 | -4.68 | 109.37 | -9.04 |
| SONN | Sonnet BioTherapeutics Ho… | $1.26 | 8.43M | +87,488% | -33% | — | +67,885% | -0.19 | -2.83 | 73.88 | -0.12 | — | -2.83 | 100.00% | -63617.91% | -39929.30% | 2089.93% | 846.19% | -181.38% | -0.27 | — | 0.66 | 0.28 | 0.00 | -9218.00% | -8740.00% | -6049.00% | -625.56% | -2.68 | 614.69% | 0.00% | 0.00% | 0.00% | -0.11 | -0.16 | 72.88 | -73.78 |
| TAOX | TAO Synergies Inc. | $3.91 | 13.63M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -78.91% | 0.00% | -52.28% | 0.00 | — | 17.47 | 17.41 | 2.59 | -10000.00% | — | -564.00% | — | -4.82 | 63.45% | — | -7.40% | — | — | — | — | — |
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
- CEO
- John Duke
- Employees
- 330
- Beta
- 1.56
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.33 ÷ $6.36) − 1 = -94.81% (DCF, example).